FDA Priority Review For Some Generics Urged To Address 'Market Failure'
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Aging Committee hearing addresses generic drug priority reviews at FDA, compounding and publicizing a “watch list” of off-patent drugs with no competition as ways of deterring dramatic price increases for such products.